Flunarizine

As a commonly used calcium channel blocker in clinical practice, flunarizine can selectively block excessive calcium ions from entering vascular smooth muscle cells to relieve vasospasm, and at the same time improve vestibular microcirculation and inhibit abnormal discharge of neurons. This drug is mainly used for the preventive treatment of typical or atypical migraine, as well as the control of vertigo symptoms caused by vestibular dysfunction. The applicable population covers adults and children over 6 years old with recurrent migraine attacks, and it is one of the basic drugs for the long-term management of chronic symptoms in neurology.

The global market size of flunarizine is approximately USD 420 million, with a compound annual growth rate of 3.1% in the past three years. The growth momentum mainly comes from the increase in the penetration rate of migraine preventive drugs in primary medical institutions. In the domestic market, generic drugs account for more than 95% of the share. Flunarizine has been included in the 7th batch of nationally organized drug centralized procurement, and the price reduction of the selected preparations has reached 76%, which directly drives the annual growth rate of upstream API demand to increase to more than 8%. The leading API manufacturers are concentrated in East China.

The original research enterprise of flunarizine is Janssen Pharmaceutica N.V. of Belgium, with the trade name "Sibelium". The core compound patent of flunarizine expired globally in 2000. At present, the domestically approved original research dosage form is capsule with a specification of 5mg, which has been included in the *Catalogue of Reference Preparations for Chemical Drugs* issued by the National Medical Products Administration. According to the domestic API registration platform, 12 enterprises have completed the A-status registration of flunarizine APIs, which can be legally supplied to preparation manufacturers. The domestically approved preparation varieties cover multiple dosage forms including capsules, tablets and dropping pills. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of flunarizine impurity reference standards, which meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA. Most products are in regular stock, and orders placed before 16:00 can be shipped on the same day, which can fully meet various needs of API R&D, quality research and routine production testing.